Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.

The New England journal of medicine - 3 Jan 2013

Gane Edward J, Stedman Catherine A, Hyland Robert H, Ding Xiao, Svarovskaia Evguenia, Symonds William T, Hindes Robert G, Berrey M Michelle

Abstract excerpt

BACKGROUND: The standard treatment for hepatitis C virus (HCV) infection is interferon, which is administered subcutaneously and can have troublesome side effects. We evaluated sofosbuvir, an oral nucleotide inhibitor of HCV polymerase, in interferon-sparing and interferon-free regimens for the treatment of HCV infection. METHODS: We provided open-label treatment to eight groups of patients. A total of 40...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Therapy, Combination
Share to Hemoglobins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon-alpha

Share to Polyethylene Glycols

Share to Ribavirin

Share to Sofosbuvir

Share to Uridine Monophosphate

Share to Viral Nonstructural Proteins

Source

Identifiers

PMID: 23281974
DOI: 10.1056/NEJMoa1208953

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.PMID 23281974Read ↗

Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infectionSemantic proximity Read ↗

Sofosbuvir for previously untreated chronic hepatitis C infection.Semantic proximity Read ↗

Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection.Semantic proximity Read ↗

What is the role of sofosbuvir in treating hepatitis C infection?Semantic proximity Read ↗

Sofosbuvir and ribavirin in HCV genotypes 2 and 3.Semantic proximity Read ↗

Hepatitis C therapy with HCV NS5B polymerase inhibitors.Semantic proximity Read ↗

Antiviral therapy with nucleotide polymerase inhibitors for chronic hepatitis C.Semantic proximity Read ↗

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial.Semantic proximity Read ↗

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.Semantic proximity Read ↗

Sofosbuvir in the treatment of chronic hepatitis C: new dog, new tricks.Semantic proximity Read ↗

Sofosbuvir/velpatasvir regimen promises an effective pan-genotypic hepatitis C virus cure.Semantic proximity Read ↗

Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.